Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy

Keisuke Tamari; Fumiaki Isohashi; Yuichi Akino; Osamu Suzuki; Yuji Seo; Yasuo Yoshioka; Yoshito Hayashi; Tsutomu Nishida; Tetsuo Takehara; Masaki Mori; Yuichiro Doki; Kazuhiko Ogawa

Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy

Keisuke Tamari, Fumiaki Isohashi, Yuichi Akino, Osamu Suzuki, Yuji Seo, Yasuo Yoshioka, Yoshito Hayashi, Tsutomu Nishida, Tetsuo Takehara, Masaki Mori, Yuichiro Doki, Kazuhiko Ogawa

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixtynine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 >41.6%, age >66 years, body mass index (BMI) >19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.

Original language	English
Pages (from-to)	7389-7393
Number of pages	5
Journal	Anticancer research
Volume	34
Issue number	12
Publication status	Published - Dec 1 2014
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy'. Together they form a unique fingerprint.

Cite this

Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy. / Tamari, Keisuke; Isohashi, Fumiaki; Akino, Yuichi; Suzuki, Osamu; Seo, Yuji; Yoshioka, Yasuo; Hayashi, Yoshito; Nishida, Tsutomu; Takehara, Tetsuo; Mori, Masaki; Doki, Yuichiro; Ogawa, Kazuhiko.

In: Anticancer research, Vol. 34, No. 12, 01.12.2014, p. 7389-7393.

Research output: Contribution to journal › Article › peer-review

Tamari, Keisuke ; Isohashi, Fumiaki ; Akino, Yuichi ; Suzuki, Osamu ; Seo, Yuji ; Yoshioka, Yasuo ; Hayashi, Yoshito ; Nishida, Tsutomu ; Takehara, Tetsuo ; Mori, Masaki ; Doki, Yuichiro ; Ogawa, Kazuhiko. / Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy. In: Anticancer research. 2014 ; Vol. 34, No. 12. pp. 7389-7393.

@article{46efddbd3e3747cb9969e796f664bb09,

title = "Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy",

abstract = "Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixtynine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 >41.6%, age >66 years, body mass index (BMI) >19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.",

author = "Keisuke Tamari and Fumiaki Isohashi and Yuichi Akino and Osamu Suzuki and Yuji Seo and Yasuo Yoshioka and Yoshito Hayashi and Tsutomu Nishida and Tetsuo Takehara and Masaki Mori and Yuichiro Doki and Kazuhiko Ogawa",

year = "2014",

month = dec,

day = "1",

language = "English",

volume = "34",

pages = "7389--7393",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "12",

}

TY - JOUR

T1 - Risk factors for pericardial effusion in patients with stage i esophageal cancer treated with chemoradiotherapy

AU - Tamari, Keisuke

AU - Isohashi, Fumiaki

AU - Akino, Yuichi

AU - Suzuki, Osamu

AU - Seo, Yuji

AU - Yoshioka, Yasuo

AU - Hayashi, Yoshito

AU - Nishida, Tsutomu

AU - Takehara, Tetsuo

AU - Mori, Masaki

AU - Doki, Yuichiro

AU - Ogawa, Kazuhiko

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixtynine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 >41.6%, age >66 years, body mass index (BMI) >19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.

AB - Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixtynine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 >41.6%, age >66 years, body mass index (BMI) >19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.

UR - http://www.scopus.com/inward/record.url?scp=84918558524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918558524&partnerID=8YFLogxK

M3 - Article

C2 - 25503178

AN - SCOPUS:84918558524

VL - 34

SP - 7389

EP - 7393

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -